Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 4/20 | 0.45 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.45 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MPI | P34949 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | G6PD | P11413 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3237524 | 0.88 | ERN1 (0.56) | MAOBPOLBEIF4HGAAALDH1A1 | |
| SCHEMBL9743634 | 0.85 | CNR2 (0.43) | MAOBPOLBEIF4HAMY1AMEN1 | |
| SCHEMBL9743631 | 0.85 | CNR2 (0.43) | MAOBPOLBEIF4HAMY1AMEN1 | |
| SCHEMBL9742095 | 0.84 | TRPA1 (0.61) | MAOBPOLBEIF4HMEN1KMT2A | |
| SCHEMBL7144664 | 0.84 | PTPN1 (0.58) | MAOBPOLBMEN1KMT2AKDM4E | |
| SCHEMBL21686 | 0.84 | TRPA1 (0.61) | MAOBPOLBEIF4HMEN1KMT2A | |
| SCHEMBL30728934 | 0.84 | TRPA1 (0.61) | MAOBPOLBEIF4HMEN1KMT2A | |
| SCHEMBL7144667 | 0.84 | PTPN1 (0.58) | MAOBPOLBMEN1KMT2AKDM4E | |
| SCHEMBL9743124 | 0.79 | IAPP (0.40) | MAOBPOLBEIF4HAMY1AMEN1 | |
| SCHEMBL4934692 | 0.79 | MAOB (0.42) | MAOBPOLBEIF4HAMY1AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024238399-A1 | METHODS OF MANUFACTURING ADENO-ASSOCIATED VIRAL VECTORS | SIREN BIOTECHNOLOGY, INC. (US) | 2024-11-21 | — | — | WO | claimed |
| EP-4427758-A1 | NEW SYNERGISTIC ANTI-INFLAMMATORY, ANTIOXIDANT AND ANTIBACTERIAL ASSOCIATION | NOOS S.r.l. (IT) | 2024-09-11 | — | — | EP | claimed |
| CN-117222406-A | Compounds for the treatment and prophylaxis of covd-19 | T·塞凯赖什 | 2023-12-12 | — | — | CN | claimed |
| US-20230141224-A1 | FIBROBLAST MEDIATED EXPANSION AND AUGMENTATION OF IMMUNE REGULATORY CELLS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | FIGENE, LLC | 2023-05-11 | — | — | US | claimed |
| EP-4142751-A1 | FIBROBLAST MEDIATED EXPANSION AND AUGMENTATION OF IMMUNE REGULATORY CELLS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | Figene, LLC (US) | 2023-03-08 | — | — | EP | claimed |
| WO-2021202032-A1 | FIBROBLAST MEDIATED EXPANSION AND AUGMENTATION OF IMMUNE REGULATORY CELLS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | FIGENE, LLC (US) | 2021-10-07 | — | — | WO | claimed |
| JP-2011528336-A | — | — | 2011-11-17 | — | — | JP | claimed |
| EP-2315583-A2 | FORMULATION FOR IMPROVING THE BIOAVAILABILITY OF A HYDROPHOBIC MOLECULE | Yvery (FR) | 2011-05-04 | — | — | EP | claimed |
| WO-2010007252-A2 | FORMULATION FOR IMPROVING THE BIOAVAILABILITY OF A HYDROPHOBIC MOLECULE | YVERY (FR) | 2010-01-21 | — | — | WO | claimed |
| EP-4678169-A1 | COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF INFECTIONS WITH RSV | Szekeres, Thomas (AT) | 2026-01-14 | — | — | EP | disclosed |
| EP-4516298-A1 | STILBENE COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF INFECTIONS WITH CYTOMEGALOVIRUS (CMV) | Szekeres, Thomas (AT) | 2025-03-05 | — | — | EP | disclosed |
| EP-4313010-B1 | COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF COVID- 19 | SZEKERES THOMAS (AT) | 2025-02-19 | — | — | EP | disclosed |
| WO-2024238399-A1 | METHODS OF MANUFACTURING ADENO-ASSOCIATED VIRAL VECTORS | SIREN BIOTECHNOLOGY, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| EP-4427758-A1 | NEW SYNERGISTIC ANTI-INFLAMMATORY, ANTIOXIDANT AND ANTIBACTERIAL ASSOCIATION | NOOS S.r.l. (IT) | 2024-09-11 | — | — | EP | disclosed |
| EP-1654210-B1 | STILBENE DERIVATIVES AND THEIR USE IN MEDICAMENTS | SZEKERES THOMAS (AT) | 2008-07-30 | — | — | EP | disclosed |
| US-20070191627-A1 | Stilbene derivatives and their use in medicaments | SZEKERES THOMAS | 2007-08-16 | — | — | US | disclosed |
| WO-2007002973-A2 | USE OF STILBENE DERIVATIVES FOR THE PRODUCTION OF MEDICAMENTS FOR THE TREATMENT OF SOLID TUMOURS | MEDIZINISCHE UNIVERSITÄT WIEN (AT) | 2007-01-11 | — | — | WO | disclosed |
| EP-1654210-A2 | STILBENE DERIVATIVES AND THEIR USE IN MEDICAMENTS | Szekeres, Thomas (AT) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005102298-A1 | MEDICAL SUBSTANCE MIXTURES CONTAINING RESVERATROL OR RESVERATROL-DERIVATIVES, IN ADDITION TO THE USE THEREOF IN THE PRODUCTION OF MEDICAMENTS | SZEKERES THOMAS (AT) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005016860-A2 | STILBENE DERIVATIVES AND THEIR USE IN MEDICAMENTS | SZEKERES THOMAS (AT) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191627-A1 | Stilbene derivatives and their use in medicaments | PTGS2, PTGS1, PTGER2 | MAOB 496/4885POLB 1365/4885EIF4H 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.